ASIC approves C3 name change

By Dylan Bushell-Embling
Tuesday, 17 June, 2008

The Australian Securities and Investments Commission (ASIC) has approved the request by Clinical Cell Culture (ASX: CCE) to rename itself Avita Medical.

The name change will take effect on June 26, when Avita will begin trading on the ASX under the code AVH.

Organoid platform enables closer study of bat-borne viruses

Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...

Global study finds 250 genes linked to OCD

Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...

TGA approves therapy for paediatric growth hormone deficiency

The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...

Content from other channels on our network

Recycled water to keep Victorian sporting grounds green

Productivity Summit announcement welcomed

ABB receives EPD status for gearless mill drive ring motor

From Crisis to Control: AI Offers New Hope for Water Management

Urban mining to diversify Australia's critical metal supply chain

Could this game wave goodbye to nerve pain?

Inaugural Hospital + Healthcare Excellence Awards — nominations open

Westmead Hospital to gain $492m pathology hub

Nearing the peak: NSW elective surgery waiting list figures

Investment in new Bankstown Hospital reaches record $2 billion

From smart to vulnerable: The hidden costs of the digitalisation of utilities

Copper SA partners with Aurizon for copper logistics

Robotic storage system transforms NZ pharmaceuticals warehouse

BHP launches Industry AI Hub in Singapore

Claroty introduces an impact-centric approach to CPS risk reduction